Healthcare >> CEO Interviews >> October 1, 2001
VINCENT F. SIMMON was appointed President and Chief Executive Officer
and a Director of Cortex Pharmaceuticals, Inc., in May 1996 and served
as the acting Chief Financial Officer and Secretary of the company from
October 1998 to December 1999. From 1994 to 1995, Dr. Simmon served as
Chairman, President and Chief Executive Officer of Prototek, Inc., a
privately-held biopharmaceutical company focusing on the development of
protease inhibitors. From 1990 to 1994, Dr. Simmon served as President,
Chief Executive Officer and a Director at Alpha 1 Biomedicals, Inc., a
biotechnology company. From 1985 to 1990, Dr. Simmon served as Vice
President for Biomedical and Biotechnology Research at W. R. Grace & Co.
From 1979 to 1985, Dr. Simmon served in varying capacities including
Senior Vice President of Research and Development for Genex Corporation,
a genetic engineering company; and from 1973 to 1979 in varying
capacities including Assistant Director, Department of Technology for
SRI International, a consulting company. Dr. Simmon has served as a
governor of the Emerging Companies Section of BIO (Biotechnology
Industrial Organization) and a Director of the Chemical Industries
Institute for Toxicology (Research Triangle Park). Dr. Simmon holds a BA
in Biology and Chemistry from Amherst College, an MS from the University
of Toledo in Plant Physiology and a PhD in Molecular Biology from Brown
University. Dr. Simmon was a postdoctoral Fellow from 1971 to 1973 at
Stanford University. Dr. Simmon sits on the Boards of Directors of LINC
(Life Sciences Industry Council) and Thuris Corporation, a privately-
held company. Profile
an overview of the company as it is now?
Dr. Simmon: The company was founded in 1987 and went public in 1989. In
1993
